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Background:Recent developments in mobile technology have enabled the investigation
of human movements and mobility under natural conditions, i.e., in the home
environment. Iron accumulation in the basal ganglia is deleterious in Parkinson’s disease
(i.e., iron accumulation with lower striatal level of dopamine). The effect of iron chelation
(i.e., re-deployment of iron) in Parkinson’s disease patients is currently tested in a
large investigator-initiated multicenter study. Conversely, restless legs syndrome (RLS)
is associated with iron depletion and higher striatal level of dopamine. To determine from
animal models which movement and mobility parameters might be associated with iron
content modulation and the potential effect of therapeutic chelation inhuman.
Methods: We recapitulated pathophysiological aspects of the association between
iron, dopamine, and neuronal dysfunction and deterioration in the basal ganglia, and
systematically searched PubMed to identify original articles reporting about quantitatively
assessed mobility deficits in animal models of brain iron dyshomeostasis.
Results: We found six original studies using murine and fly models fulfilling the inclusion
criteria. Especially postural and trunk stability were altered in animal models with iron
overload. Animal models with lowered basal ganglia iron suffered from alterations in
physical activity, mobility, and sleep fragmentation.
Conclusion: From preclinical investigations in the animal model, we can deduce
that possibly also in humans with iron accumulation in the basal ganglia undergoing
therapeutic chelation may primarily show changes in physical activity (such as daily
“motor activity”), postural and trunk stability and sleep fragmentation. These changes
can readily be monitored with currently available mobile technology.
Keywords: Parkinson’s disease, restless legs syndrome, mobility assessment, iron, animal models
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BACKGROUND
Mobile technology (mainly reflected by “wearables”) is a
dynamically developing field with relevant implications for
the health and fitness sector, and also for medical routine
and clinical trials (1). Wearables for the assessment of
movements and mobility are microelectromechanical systems
with multiple degrees of freedom (DOF; e.g., 3D accelerometers,
3D gyroscopes, and 3D magnetometers) (2, 3). They enable
continuous assessment during 24 h over many days, and make
possible data collection and evaluation of disease progression and
response to treatment based on uninstructed, unsupervised, and
unobserved movements (1, 3–5). It seems realistic that such data
will soon be used as complementary information for treatment
decisions in diseases associated with movement deficits, such as
Parkinson’s disease (PD) (6) and restless legs syndrome (RLS).
This development is, at least partly, driven by accumulating
evidence that humans perform similar movements differently in
the home environment and in the doctor’s practice, hospital and
research lab, especially with regard to daily-relevant movements
(4, 7). Therefore, clinical assessment may not always reflect daily-
relevant information for the affected. Moreover, physical activity
and mobility can by definition only be evaluated in the natural
environment of the user, and some movement abnormalities,
such as those happening during sleep, may occur only in the
“unobserved,” but not in the usual professional, environment (8).
Specific algorithms for the detection of such movements in the
natural environment are currently developed by us and other
groups (9–12).
While the usage of mobile technology is widely applied in
humans, animal research also benefits from the technological
development in movement and mobility assessment, as
evidenced by behavioral measures in scientifically used animal
models, animal husbandry, or the wild (13, 14). So far translation
of quantitative data of movement and mobility from animal
models to human has not been performed but it seems likely
that quantitatively assessed movement changes in animals
correspond to human diseases. Therefore, they may inform
about (corresponding) human behavior.
In this review we aim to transfer pathophysiology of disturbed
brain iron homeostasis in phenomenology of established PD
and RLS animal models (Tables 1, 2). Our approach is based
on accumulating evidence that iron accumulation in the basal
ganglia leads to a PD-like, hypokinetic movement deficit, and
lack of iron may be associated with a certain level of hyperkinetic
movements resembling RLS features. We will discuss animal
models associated with iron overload (25) and iron deficiency
(26). This discussion should help defining a set of promising
parameters to monitor changes of movement and mobility in a
currently built mobile technology-based dataset obtained from
the natural environment of PD patients under investigational
treatment with an iron chelator (FAIR PARK II study, www.
fairpark2.eu). FAIR PARK II is an investigator-initiated trial
Abbreviations: PD, Parkinson’s disease; RLS, restless legs syndrome; ID, iron
deficiency; CSF, Cerebrospinal fluid; SN, substantia nigra; MPTP, 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine.
testing the effects of a conservative iron chelation therapy -i.e.,
chelation and redeployment of iron to limit iron sequestration
and iron deficit- on the progression of handicap in PD.
MAIN TEXT
Iron in PD
Several post mortem and imaging (MRI and ultrasound)
studies have shown that iron concentration is an important
susceptibility factor for nigrostriatal degeneration and that
basal ganglia iron concentration is higher in PD patients
compared to controls (27, 28). Increased echogenicity of the
substantia nigra (SN) on ultrasound is a typical sonographic
finding in PD, and sonographic signal intensity of the SN is
related to tissue iron content with higher iron levels being
associated with increased echogenicity in both animal models
and post mortem findings in human (29–31). Recent studies
showed that mutant and wild-type alpha-synuclein may have
differential interaction with iron and mutant alpha-synuclein
toxicity could be preferentially exacerbated by iron. Iron
overload could selectively influence mutant alpha-synuclein
toxicity and disease phenotypes (32). Overall, the iron content
is elevated in the SN of PD patients (33, 34). A conservative
repositioning strategy of iron in an animal model using the iron
chelator desferrioxamine retarded 6-hydroxydopamine-induced
degeneration of nigrostriatal dopamine neurons (35). In PD
application of deferiprone improved the motor part of the
Unified PD rating scale (25).
Iron and Dopamine in PD
Although brain iron pathways and their relevance to PD are
not entirely clarified, it is suggestive that iron is important
in PD pathophysiology (25, 36). Iron is a significant co-factor
in dopamine biosynthesis and is intricately involved in the
regulation of dopamine levels in the brain. Several pathways
are involved in dopamine metabolism. Iron concentration in
neurons is high so that toxic dopamine metabolites occur (37).
In neurons a high iron content is detected in the cytoplasm.
In this cellular compartment the formation of toxic dopamine
metabolites takes place (38, 39). Iron accumulation is found
in several brain regions in synucleinopathies whereat only
specific regions are vulnerable for neuronal loss (40). Factors
triggering neuronal loss associated are still poorly understood.
Neuromelanin is produced in the substantia nigra, pars
compacta SNc whereas dopamine is converted to o-quinones
(41). Neurotoxic intermediates may result from iron mediated
oxidation reactions. The interaction of iron and dopamine has
been suggested as major player in the development of neuronal
cell loss in defined brain regions (i.e., SNc).I. Neuromelanin
as intracellular iron storage is of particular importance in PD
(42). Accumulation and overload of iron suggested to increase
oxidative stress has be demonstrated in the diseased PD brain
(43, 44). The direct interaction of neuromelanin with the
protein alpha-synuclein has also been accused to trigger neuronal
damage. Alpha-synuclein gene dosages are higher in individual
melanized neurons, triggering cell death to a greater extent in PD
compared the healthy controls (45–47). Finally, microglia might
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TABLE 1 | Animal models for elevated brain iron.
Author Animal model Iron changes Movement /
mobility outcome
parameter
Result Suggested relevance
for human mobility and
movements
Vidal et al. (15) Transgenic mouse of a human
ferritin light polypeptide cDNA
carrying a thymidine and
cytidine insertion at position
498 (FTL498 499InsTC)
Iron overload in the
putamen, globus
pallidus, thalamus,
cerebellum,
hippocampus, and
the olfactory bulb
(i) Latency to fall
from the rotarod
[accelerating
rotarod (16)]
(ii) Position reflexes
during suspension of
the mice by
their tails
(iii) grooming
and incoordination
(i) Mutated mice showed
shorter latency to fall from the
rotarod
(ii) Mutated mice showed
flexion of front and hindlimbs
inward, with paws clasping
together and drawing in
toward the body and also
hunchbacked posture when
walking, low body position
with some degree of lordosis,
and shuffling gait with
dragging hindlimbs
(iii) Mutated mice showed
abnormal grooming and
incoordination
Dynamic balance
disturbance
Reduction of position
reflexes
Posture deficits
Reduced activity/apathy
Impaired fine-motor
dexterity and
motor coordination
Levenson et al.
(17)
Wild type mouse with (Fe-)
and without dietary iron
restriction (Fe+) treated with
MPTP
MPTP leads to iron
overload in
TH-positive neurons
(18)
Number of falls from
the rotarod within
5min (19)
MPTP-treated Fe+ mice (but
not MPTP-treated Fe- mice)
had higher number of falls
from the rotarod and lower
total amount of time spent on
the rotarod
Dynamic balance
disturbance
Zhu et al. (20) Drosophila melanogaster with
(Fe–) and without dietary iron
restriction (Fe+)
overexpressing A53T or A30P
alpha-synuclein
Iron overload in
dopaminergic
neurons in mutated
Fe+ animals
Climbing ability in a
plastic column
(Negative geotaxis
assay)
Fe+ mutant flies showed
decreasing geotaxis
performance
Reduced motor activity,
reduced amount of
voluntary movements
Maccarinelli
et al. (21)
Transgenic mouse of a human
ferritin light polypeptide cDNA
carrying a thymidine and
cytidine insertion at position
498 (FTL498 499InsTC)
Iron overload in the
putamen, globus
pallidus, thalamus,
cerebellum,
hippocampus, and
the olfactory bulb
Latency to fall from
the rotarod before
the end of the 5-min
test session
[accelerating rotarod
(22)]
Both the mutation and age
had a negative effect on the
latency (i.e., shorter) to fall
from the rotarod
Dynamic balance
disturbance
be activated by neuromelanin leading to an outspread of neuronal
degeneration in brain tissue (48).
Iron in RLS
RLS is the most frequent movement disorder with potentially
severe disease burden due to physical and mental health. The
clinical key features include sensory symptoms (restlessness,
urge to move), unpleasant sensations (paresthesia, pain), and
motor symptoms (periodic limb movements, further motor
manifestations) (49). Low brain iron (reflected by, e.g., ferritin)
despite normal peripheral iron plays a major role through its
effects on the dopaminergic system (26, 50, 51). Cerebrospinal
fluid (CSF) and serum ferritin are positively correlated. Low
CSF ferritin is accompanied by low serum ferritin, particularly
in cases diagnosed with iron deficiency anemia. RLS prevalence,
as expected, is about five times more prevalent in patients with
iron deficiency anemia than in the general population (52, 53).
Iron deficiency anemia may predispose to the development
of RLS but is no precondition as about 5% of the general
population are affected from RLS (53). Beyond iron deficiency
itself, the interaction of low CSF ferritin with other secondary
biochemical changes and genetic factors lead to RLS symptoms.
Iron replacement therapy shows inconsistent results so that
general guidelines for treatment do not unambiguously commit
to iron treatment (54, 55). Iron deficiency in brain may be related
to a loss of iron regulatory protein activity, the function of
blood-brain barrier, where endothelial cells act as iron reservoir
for the brain. A dysfunction of iron regulatory proteins in the
microvasculature might lead to a decrease of iron storage in
endothelial cells.
Most probably, RLS is determined by environmental factors
and genetical modifiers of brain iron homeostasis leading to a
dysfunction of the cortico-striatal-thalamic-cortical circuit.
Iron and Dopamine in RLS
Using a post-weaning, diet-induced iron deficiency (ID)
condition in rodents to reduce SN iron, studies have
demonstrated that iron deficiency increases extracellular
striatal dopamine, decreases striatal dopamine-2 receptor
density, and diminishes dopamine transporter density and
function in vitro but not dopamine release (56). Similar
to the findings in the iron deficiency rodent, RLS striatal
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TABLE 2 | Animal models for reduced brain iron.
Author Animal model Iron changes Movement/mobility
outcome parameter
Result Suggested
relevance for free
human movement
Freeman et al.
(23)
Drosophila
melanogaster with
loss of functional
BTBD9 (Drosophila
homolog CG1826)
Iron depletion in
dopaminergic
neurons (BTBD9
modulates ferritin
levels through
reducing iron
regulatory protein-2
levels)
Walking speed, total distance
covered in 5min, number of
walks between two black
bars, total walking time,
number of breaks, average
walking bout distance
Mutated flies showed increased
total distance, increased number of
walks between the two black bars,
increased total walking time,
decreased number of breaks and
increased walking bout distance
Increase of physical
persistence and
daily activity
DeAndrade
et al. (24)
BTBD9 knockout
mouse
Iron depletion in
dopaminergic
neurons (23)
Total distance in the open field
chamber and during wheel
running
Mutated mice showed increased
total distance during both
experiments and were more active
during dark periods of the day
Change of physical
activity during the
day and especially at
night
dopaminergic pathology has shown diminished dopamine-2
receptors (56). Iron deficiency in rodents lead to decreased
ventral midbrain iron concentrations and to changes in the
dopamine system that mimic many of the dopaminergic changes
seen in RLS patient where low SN iron is a known pathology
of the disease (56). It is well-known that RLS occurs with
increased dopamine in the striatum (57, 58). Adding iron to
the ventral midbrain leads to increased extra-cellular dopamine
in the striatum (56). Adding iron to the striatum had no
effect on its dopamine levels. Thus, the increase in iron seen
in ventral midbrain with intravenous iron treatment seems
to induce changes in striatal dopamine seen in RLS itself.
Biochemical studies on the effect of iron in brain indicated
that iron regulates hypoxia inducible co-factor pathways,
leading to an upregulation of proteins that are involved in
angiogenesis, erythropoiesis, cell survival, and proliferation. The
interplay between compromised neuronal iron uptake and the
functions of the neuromelanin-containing and dopaminergic
cells might lead to RLS pathology (59). Decreased density
of dopamine-1 and dopamine-2 receptors are detected in
conditions of iron deficiency, indicating that iron affects the
brain dopaminergic transmission in different ways (60). In RLS it
has additionally been reported that A 10 and A11 dopaminergic
neurons, localized in the hypothalamus, might be involved
in disease mechanism (1). It has been suggested that these
neurons are connected to the spinal cord in mice modulating
spinal excitability leading to alterations. These changes lead to
disturbed sensory processing of leg afferents projecting in brain
stem structures (2).
Iron dyshomeostasis in SN is characteristic for both PD and
RLS. The misdistribution of iron leads to iron deposits in PD and
iron deficiency in RLS, presenting mechanistically a “relatively
inverse” picture between PD and RLS. However, the picture
may be much more complex because the misdistribution can
also lead to both deposits and deficiency at the level of cell
compartments (e.g., mitochondria vs. cytoplasma), cells (neurons
vs. astrocytes and microglia) and tissue (e.g., SN vs. striatum
and other regions). The complex picture can explain why some
patients present both PD and RLS (61).
ANIMAL MODELS FOR MOVEMENT
DISORDERS ASSOCIATED WITH IRON
METABOLISM
Based on the assumption that animal models associated with
iron dyshomeostasis in the brain, more specifically in the
basal ganglia, may have the potential to report about mobility
and movement patterns that may also be altered by humans
affected by the “corresponding” disease, we searched PubMed for
studies investing such animal models and including quantitative
data on mobility and movement patterns, and have been
published until September 2018 (Tables 1, 2). We used the
following search terms: “animal + iron,” “Parkinson disease
iron animal model,” “Parkinson disease iron mouse model,”
“Parkinson disease iron rat model,” “Parkinson disease iron
drosophila model,” “Parkinson disease iron activity levels mouse,”
“Iron dopaminergic system mouse model,” “iron metabolism
mouse model,” “Restless legs animal model,” “Restless legs iron
mouse model,” “Restless legs iron rat model,” “Restless legs iron
drosophila model,” and “Restless legs iron activity levels mouse.”
Articles were then checked for duplicates and for fulfilling the
inclusion criteria (animal model, direct/indirect evidence of
altered iron content in the basal ganglia, quantitative movement,
and mobility assessment). We identified nine studies whereof six
studies fulfilled these inclusion criteria and were thus included
in the final evaluation (Tables 1, 2). Four studies investigated
models with iron overload (15, 17, 20, 21) and two studies
investigated models with iron deficiency (23, 24). All but two
[drosophila melanogaster (20, 23)] were mouse models. Two
studies used the identical mouse mutant (15, 21). The six studies
are presented in following in more detail.
MOTOR BEHAVIOR IN ANIMAL MODELS
WITH ELEVATED BRAIN IRON CONTENT
Old neuroferritinopathy mutant mice, which have increased
accumulation of iron aggregates in the striatum among other
brain regions, showed a shorter latency to fall from the
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rotarod compared to WT mice (21) (Table 1). These mutant
mice presented with a progressive behavioral and motor
phenotype, consisting of abnormal grooming, tremor, posture,
and incoordination (21). Feet clasping was observed after
suspension of the mice by their tails. Moreover, they flexed their
front and hindlimbs inward, with paws clasped together and
drawn in toward the body. In contrast, WT mice demonstrated
normal limb posture when suspended by their tails. Toward
the end of the life span, mutant mice displayed a hunchbacked
posture when walking and low body position with some degree
of lordosis. They also showed a shuﬄing gait with dragging
hindlimbs, suggestive of a reduction of position reflexes. In these
mice, iron was elevated in multiple brain regions but highly
accumulated in the dorsal striatum that is in humans known to
mediate motor and executive functions (e.g., inhibitory control).
The connection between the location of the damage and observed
mobility deficits possess a degree of similarity tomotor symptoms
occurring in PD.
In another study using the same transgenic mice, the analysis
of motor performance on a rotating rod revealed a significant
decrease in performance at the earliest age tested (4 months),
before an obvious clinical phenotype was observed (Table 1).
This effect was somewhat stronger after 13 months of age,
suggesting indirect iron-dependent disturbances in dynamic
balance (15). Accordingly, rise of iron deposits within a brain
region and across regions was positively associated with disease
progression in PD patients (62). Taken together, the observed
changes in mobility and movement performance of this mutant
mouse strain reflect dynamic balance disturbance and motor
coordination, reduced position reflexes, postural deficits, and
reduced physical activity. Of note, the best surrogate parameter
currently known for dynamic balance is gait variability, which
deterioration is associated with increased frequency of falls
in PD (63). This parameter (63, 64) as well as physical
activity (65, 66) can be measured with high accuracy using
mobile technology.
In a study aiming to evaluate the role of dietary iron restriction
in a mouse model of PD (Table 1), mice were fed diets containing
low (Fe-, 4 ppm) or adequate (Fe+, 48 ppm) amounts of iron for
6 weeks before the administration of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) (17). MPTP is a mitochondrial toxin
that damages nigrostriatal dopaminergic neurons and induces
PD-like symptoms. Administration of MPTP resulted in reduced
levels of dopamine and its metabolites in the striatum of Fe+
mice but not Fe- mice. Consistently, MPTP impaired postural
control as determined by the mean number of falls from the
rotarod and total time spent on the rotarod only in Fe+ mice,
but not Fe– mice (17). Iron therefore seems to favor formation
of cell death in face of other factors damaging dopaminergic
neurons. In conclusion, this study suggests that even in non-
mutant animal models reflecting (at least some aspects of)
PD, iron homeostasis influences the motor phenotype -more
FIGURE 1 | Effects of altered brain (especially basal ganglia) iron homeostasis on movements and mobility observed in animal models may translate to similar
alterations in men. (A) Low iron levels in animal models are associated with increased physical activity and with sleep fragmentation. (B) Normal iron levels are
associated with normal physical activity, normal sleep behavior, and the ability to move during sleep. (C) Increased iron levels are associated with reduced physical
activity, postural and trunk instability, and immobility while sleeping (69, 70).
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specifically dynamic balance- and that dietary iron restriction has
a beneficial effect.
Another study used a drosophila melanogaster model
overexpressing A53T or A30P alpha-synuclein with (Fe–) and
without dietary iron restriction (Fe+) (Table 1) (20). The authors
found an iron overload in dopaminergic neurons only inmutated
Fe+ animals but not in all other groups (including the mutated
Fe– group). The mutated flies without iron restriction also
performed worse in a negative geotaxis assay (a plastic column
where the flies had to climb above a certain line), suggestive of
reduced motor activity and/or reduced voluntary movements.
This study also demonstrates that iron overload, in combination
with additional factors (here PD-modulating genetic mutations),
can promote degeneration of dopaminergic neurons. These
results fit well-with the above observations of reduced physical
activity, although based on these results it is difficult to exclude
potentially contributing symptoms such as apathy and fatigue.
MOTOR BEHAVIOR IN ANIMAL MODELS
WITH REDUCED BRAIN IRON CONTENT
In BTBD9 knockout mice, a RLS model, physical activity levels,
sensory perception, sleep architecture were determined (Table 2)
(24). Mutant mice showed a significant increase in physical
activity compared with WT mice. Interestingly, the mutant mice
did not show sensory deficits during the middle of the night (the
active phase) but during the middle of the day (the rest phase),
suggesting an alteration of the circadian rhythm. To analyze sleep
architecture, the mice were implanted with a wireless telemetry
system. Mutated mice showed decreased overall sleep time but
no change in the amount of rapid eye movement sleep (24).
Although the pathophysiological aspects of the above-mentioned
association are, to our best knowledge, not yet understood, these
mobility, and movement alterations are interesting in the light
of mobile technology applied to men. This novel technology is
able to evaluate physical activity and sleep performance such as
movements during sleep (67).
In a RLS drosophila melanogaster model with loss of
functional BTBD9, increased locomotor activity was found in
a camera-based assessment of total walking distance, number
of walks, total walking time, number of breaks, and average
walking bout distance (Table 2) (23). Moreover, the mutated
animal model presented with increased sleep fragmentation,
including shorter, and more frequent sleeping bouts. The
authors hypothesized that these phenomenon are due to the
mediation of different sleep and activity phenotypes by BTBD9
(via the alteration of neurotransmission in some dopaminergic
neurons (23). Whatever the reasons for the observed phenotypes
are, mobile technology can readily and accurately assess such
movement patterns in humans (68).
CONCLUSION
Although we tried to comprehensively analyze/discuss the
articles according to our hypothesis, a not negligible limitation
of our review is that we could only include six studies to
our analysis which fulfilled the inclusion criteria. We tried
to set the review in perspective with the state-of-the art
methodology in analyzing the influence of iron on mobility in
animal models.
Our systematic evaluation of the currently available peer-
reviewed studies assessing movement and mobility in animal
models with altered brain iron suggests that elevated basal ganglia
iron leads to a decrease in motor performance, particularly
affecting postural, and trunk stability (Figure 1). Low basal
ganglia iron levels were mainly associated with increased
physical activity, mobility, and sleep fragmentation as well
as with changes of the circadian rhythm (Figure 1). The
above-mentioned mobility and movement parameters may be
particularly promising to assess effects of conservative iron
repositioning on movement and mobility in PD.
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